BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer

INTRODUCTION: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Ros, Javier, Baraibar, Iosune, Sardo, Emilia, Mulet, Nuria, Salvà, Francesc, Argilés, Guillem, Martini, Giulia, Ciardiello, Davide, Cuadra, José Luis, Tabernero, Josep, Élez, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903827/
https://www.ncbi.nlm.nih.gov/pubmed/33747149
http://dx.doi.org/10.1177/1758835921992974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903827/
https://www.ncbi.nlm.nih.gov/pubmed/33747149
http://dx.doi.org/10.1177/1758835921992974

Ejemplares similares